Daré Bioscience Reports 500% Revenue Growth but Faces $3M Net Loss in Q1 2026

Daré Bioscience, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $152,455, a significant increase of 500% compared to $25,427 in the same period last year. This growth was primarily driven by research and development services and royalty revenue from agreements with the Gates Foundation. However, the company incurred a net loss of approximately $3.0 million, a 31% improvement from the $4.4 million loss reported in the first quarter of 2025. The loss per share for the quarter was $(0.21), compared to $(0.50) in the prior year.

Total operating expenses for the quarter decreased by 37% to $2.9 million, down from $4.6 million in the previous year. This reduction was largely attributed to a significant decline in research and development expenses, which fell by 71% to $660,462, compared to $2.3 million in the first quarter of 2025. The decrease in R&D spending was influenced by increased contra R&D expenses, which offset direct program costs, and a reduction in personnel-related costs. Selling, general, and administrative expenses also saw a slight decrease of 3% to $2.2 million.

In terms of operational developments, Daré Bioscience is advancing its dual-path strategy for product commercialization, which includes pursuing both traditional FDA approval and earlier market access through Section 503B compounding. The company has launched its first compounded product, DARE to PLAY Sildenafil Cream, which is expected to begin generating revenue in the third quarter of 2026. Additionally, the company is preparing to launch its DARE to RESTORE vaginal probiotic suppositories in June 2026.

As of March 31, 2026, Daré Bioscience had cash and cash equivalents of approximately $18.5 million, down from $24.7 million at the end of 2025. The company reported a working capital of approximately $0.5 million and a deferred grant funding liability of about $18.2 million, primarily related to ongoing development programs. The company is actively seeking additional capital through its Regulation A offering and other financing options to support its operations and product development initiatives. The outlook remains cautious, with management indicating substantial doubt about the company's ability to continue as a going concern within the next 12 months, given the uncertainty surrounding future revenue generation and funding needs.